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RESUMO
Introdução: A crescente população de sobreviventes de cancro da mama tem redireccionado o interesse investigacional e prático 
para o impacto da doença e do seu tratamento nas várias áreas da qualidade de vida. A falta de questionários para avaliar de forma 
objectiva a disfunção sexual conduziu à necessidade de adaptar e validar culturalmente o Sexual Activity Questionnaire para utilização 
em Portugal. 
Material e Métodos: O Sexual Activity Questionnaire foi traduzido e retrovertido, sua versão de consenso refinada após teste de com-
preensão, e subsequentemente auto-administrado a uma amostra alargada de sobreviventes de cancro da mama em dois momentos, 
espaçados 15 dias, para julgar a sua validade e fiabilidade.
Resultados: Após alterações minor à versão de consenso, o Sexual Activity Questionnaire foi aplicado a 134 doentes. Obteve-se 
uma estrutura de três factores (75,5% da variância), compreendendo as escalas do Prazer, Hábito e Desconforto, todas com boa con-
sistência interna (α de Cronbach > 0,70), boa validade concorrente com o FACt-An e a checklist BCPT (r de Spearman > 0,65; p-value 
< 0,001) e estabilidade temporal aceitável (k de Cohen > 0,44). Foi identificada inactividade sexual em 23,9% das mulheres, devido a 
falta de interesse ou ao facto de não ter parceiro. 
Discussão: Os dados reportados pelos doentes conduziram a alterações nos cuidados prestados, que passaram a contemplar a 
oncosexologia. Estudos futuros deverão focar-se na aplicabilidade deste questionário a amostras com diferentes características e 
mesmo à população global, para se poderem generalizar os resultados.
Conclusão: A versão obtida do Sexual Activity Questionnaire é válida para avaliar a função sexual em sobreviventes de cancro da 
mama em Portugal.
Palavras-chave: Comportamento Sexual/psicologia; Estudos de Validação; Inquéritos e Questionários; Neoplasmas da Mama/psico-
logia; Portugal; Sexualidade/psicologia.
ABSTRACT
Introduction: The increasing survivor population of breast cancer has shifted research and practice interests into the impacts of the 
disease and treatment in quality of life aspects. The lack of tools available in Portuguese to objectively evaluate sexual function led to 
the development of this study, which aimed to cross-culturally adapt and validate the Sexual Activity Questionnaire for use in Portugal. 
Material and Methods: The questionnaire was translated and back-translated, refined following face-to-face interviews with seven 
breast cancer survivors, and then self-administered by a larger sample at baseline and a fortnight later to test validity and reliability.  
Results: Following cognitive debriefing (n = 7), minor changes were made and the Sexual Activity Questionnaire was then tested 
with 134 breast cancer survivors. A 3-factor structure explained 75.5% of the variance, comprising the Pleasure, Habit and Discomfort 
scales, all yielding good internal consistency (Cronbach’s α > 0.70). Concurrent validity with the FACt-An and the BCPT checklist was 
good (Spearman’s r > 0.65; p-value < 0.001) and reliability acceptable (Cohen’s k > 0.444). The Sexual Activity Questionnaire allowed 
the identification of 23.9% of sexually inactive women, for whom the main reasons were lack of interest or motivation and not having 
a partner. 
Discussion: Patient-reported outcomes led to a more comprehensive and improved approach to cancer, tackling areas previously 
abandoned. Future research should focus on the validation of this scale in samples with different characteristics and even in the overall 
population to enable generalizability of the findings. 
Conclusion: The adapted Sexual Activity Questionnaire is a valid tool for assessing sexual function in breast cancer survivors in 
Portugal.
Keywords: Breast Neoplasms/psychology; Portugal; Sexual Behavior/psychology; Sexuality/psychology; Surveys and Questionnaires; 
Validation Studies.
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INTRODUCTION
 Recent World Health Organization data showed that 
521,000 deaths of the 8.2 million deaths from cancer in 
2012 were due to breast cancer.1 In Portugal, breast has the 
highest incidence rate of all cancers (approximately 30% of 
the total of female cancer cases) with figures increasing.2 
Probably as a result of earlier detection and improved treat-
ment, mortality for breast cancer has been decreasing in 
most European countries. In Portugal, mortality decreased 
2% between 1992 and 2002,3 followed by a sharper decline 
recently.4 Breast cancer also has one of the highest survival 
rates across cancer sites and this too is increasing each 
year. In Portugal, age-standardized relative survival at one 
and at five years is 95% and 83%, respectively,5 therefore, 
there is a growing population of breast cancer survivors. 
Although the overall quality of life (QoL) of survivors is quite 
high,6 specific aspects of QoL such as fatigue, weakness, 
insomnia and sexual functioning may be particularly affec-
ted in this population.7 Sexual and fertility problems are es-
pecially prevalent.6 In one Australian study of 1,011 breast 
cancer survivors, 70% experienced sexual problems in the 
two years following diagnosis. Over 80% of these patients 
claimed to be having a satisfying sex-life prior to diagnosis. 
Those taking aromatase inhibitors were 50% more likely to 
report sexual problems than women treated with tamoxi-
fen or not having any hormonal therapy. Interestingly 77% 
women had hot flushes and night sweats which were as-
sociated with sexual difficulties.8 
 Female sexual dysfunction is multifactorial, involving 
physiological, psychological, social and economic 
components, and may be subdivided into four categories: 
hypoactive desire, arousal, orgasm and sexual pain.9 
 Some studies suggest that the incidence of sexual 
dysfunction increases as estrogen levels decrease,10 
whilst others mention increasing age,11 aspects seeming 
inter-related because menopausal symptoms occur with 
increasing age and can increase as a result of breast cancer 
therapies.12
 Breast cancer is in itself a factor for sexual dysfunction, 
but some treatments can lead to early and intensified 
menopausal symptoms.13 Surgery may also affect body 
image and self-esteem,14 though impact on sexual activity 
may vary according to surgery performed.15 
 There are scarce data concerning the prevalence 
of female sexual dysfunction in the general population; 
the few data available indicate a wide range of values.16 
Studies often include populations of different ages, with 
various morbidities, using several scales to measure sexual 
dysfunction, limiting comparisons. Lewis and colleagues 
reviewed descriptive epidemiological studies and indicated 
that one may expect to find some form of manifest sexual 
dysfunction in 40% - 45% of adult women.17 However, the 
prevalence may vary depending on the specific dysfunction 
studied e.g. sexual desire decreases with age. Certain 
comorbid conditions may influence sexual dysfunction in 
females such as diabetes and thyroid diseases, raising 
around 20% the prevalence of sexual dysfunction observed 
in premenopausal women.18, 19
 The prevalence reported among breast cancer survivors 
ranges between 37% and 51%.20 Time elapsed since 
diagnosis seems to have little effect; there are reports 
showing that the prevalence increases only 2%, when 
comparing women who finished treatment one year and ten 
years before.21
 The first-line treatment for women with breast cancer 
at the time of study in Portuguese Oncology Institute 
in Lisbon (IPOLFG) was tamoxifen alone. Recently, 
following publication of the SOFT trial, other ovarian 
suppression treatment options have been implemented 
for premenopausal women with high risk of recurrence.22 
Also, newly implemented practice guidelines indicate 
continuation of tamoxifen treatment for 10 years, following 
results the aTTom23 and the ATLAS trials.24 These changes 
in clinical practice are expected to improve direct outcomes 
from the disease but may also increase the prevalence of 
sexual dysfunction.
 The IPOLFG is a specialized hospital for cancer care, 
distinguished by its advanced treatment options, the 
completeness of its registry, its involvement in oncology 
research and its interest in the development of new absent 
areas of therapy. With increasing survival for breast 
cancer, focus has been given to the evaluation of specific 
areas of QoL of cancer survivors that may need additional 
care, such as sexual life. The lack of treatment of sexual 
dysfunction has been reported internationally to be as high 
as 90%.25 IPOLFG at the time did not offer patients specific 
help with sexual problems, so wanted to assess the need 
for developing a sexual-oncology clinic. Consequently a 
validated tool was required for use in Portugal to measure 
sexual activity. 
 At the time of the study two tools were available. The 
Female Sexual Function Index, a 19-item questionnaire 
addressing the four clinical entities defined by the DSM-IV, 
that had been used in a 96 generic patient sample (both 
genders) indicating 40% of changes in the female sexual 
desire.26 This questionnaire is currently validated for 
Portugal,27 but at the time this study began only a Brazilian 
version existed.28
 The second available questionnaire was the Short 
Personal Experiences Questionnaire, which had been 
used in a multicentre study involving 12 countries, 
including Portugal.29 However, the outcome measure was 
the frequency of sexual activity and not the prevalence of 
sexual dysfunction, which is a different aspect likely to be 
influenced by the country of origin. 
 Additional literature search suggested the Fallowfield’s 
Sexual Activity Questionnaire (SAQ) to be the measurement 
tool with most advantages and vaster experience in 
cancer research. This tool evaluates sexual dysfunction 
in three domains: pleasure, discomfort and habit, with 
their correlation seeming to vary according to the groups 
of patients being compared.30 Nonetheless, SAQ has been 
used in various countries, maintaining its original 3-domain 
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structure and good psychometric properties.31 
 Our ultimate goal, the thorough identification and 
quantification of sexual dysfunction among female breast 
cancer survivors, as a basis for the development of a 
multidisciplinary approach to treatment covering all affected 
areas of QoL, required us first to cross-culturally adapt and 
validate the SAQ in Portuguese.
MATERIAL AND METHODS
Study design and setting
 An exposure cohort of patients treated at IPOLFG 
between 2008 and 2010 was constituted and followed 
during 15 days for validation purposes. The study 
comprised the translation and back translation,32 followed 
by the evaluation of the psychometric properties of the 
Portuguese version (Appendix 1, available at: http://www.
actamedicaportuguesa.com/revista/index.php/amp/article/
view/7389/7389_Appendix01.pdf).
Population
 The population of interest for validation purposes was 
women with local breast cancer (stages I to III), diagnosis 
histologically confirmed < 10 years before, pre-menopausal 
or aged ≤ 50 years at the time of diagnosis, with complete 
treatment (surgery, chemotherapy, or radiotherapy, except 
for hormonotherapy) and monitored at IPOLFG, with no 
clinical manifestations of disease at the time of study (full 
remission) and being able to read and write. Women with 
chronic psychiatric disease (treated by a psychiatrist and 
medicated for at least six months) were excluded. 
Sample
 Three samples were constituted for the different stages 
of questionnaire validation. The first sample for face and 
content validation of the SAQ, comprised seven women 
selected at the oncology appointment by two of the medical 
researchers (AM; SB), aiming to represent a range of 
educational levels. 
 A second sample was randomly extracted from the 
cancer registry database, and women were then contacted 
to participate in the study. The estimated sample size was 
100, considering the scale has 20 items and 3 domains, 
following recommendations.33 This sample cross-sectionally 
tested construct validity, internal consistency, discriminant 
validity and concurrent validity. 
 A third sample was also extracted from the cancer 
registry database, aiming for a minimum of 30 participants, 
as indicated in previous work, where those having the 
nearest medical oncology appointment were invited to 
participate in the study. These answered the SAQ on 
the day of medical appointment and received a second 
questionnaire to be answered 15 days after and sent using 
a reply-paid envelope, to test temporal stability, as a form of 
reliability.34
Recruitment method
 Study participants identified in the cancer registry 
database, by random extraction, and subsequently clinical 
records were verified to ensure it was a remission case. For 
all confirmed cases, the medical doctor was contacted to 
recruit the patient at the nearest scheduled appointment. 
On that occasion, the patient was approached by one 
of the researcher nurses (EC; FF) and informed (orally 
and in written) about the study goals. Patients declining 
participation were asked to fill in a refusal form and those 
accepting to participate signed an informed consent form 
prior to receiving the questionnaires. Patients received 
two sets of questionnaires, differentiated by color, one 
completed on the day of the medical appointment and 
another answered 15 days later. Patients received reply-
paid envelopes and reminder phone calls to minimize drop-
outs. 
Questionnaires
 Participants were asked to answer the SAQ and the 
Breast Cancer Prevention Trial Symptom Checklist (BCPT) 
in two moments 15-days apart and to answer the Hospital 
Anxiety and Depression Scale (HADS) and the Functional 
Assessment Cancer Trial-Anemia (FACT-An) at baseline.
 The SAQ is divided into three sections: 1) a screening 
section where existence of a partner and sexual activity is 
assessed; 2) evaluation of the reasons for sexual inactivity 
(when applicable) and; 3) 10 statements to evaluate sexual 
function, contributing to three domains: pleasure (six items), 
discomfort (two items) and habit (one item). The pleasure 
and habit domains are rated in a direct manner, i.e., the 
higher the score, the more pleasure and habit, as these 
affect positively sexual function. The discomfort scale is 
interpreted in a reverse way, where higher scores indicate 
more discomfort, as this affects negatively sexual function.
 The HADS generates two scores, referring to 
depression and anxiety, where higher values represent 
higher impairment, i.e., more depressed and/or anxious.35 
The FACT-An comprises various subscales, evaluating 
physical, social, emotional and functional well-being, in 
addition to fatigue (a subscale of anemia), which overall 
provide a measure of the QoL of women with cancer. The 
higher the score obtained in the FACT-An, the better the 
patient’s QoL.36
Measurement properties and statistics
 Data collected for analysis was first stored in a MS 
Access 2000 database. Statistical software R 3.1.137 was 
used for statistical tests and multivariate analysis (Principal 
Component Analysis - PCA). The validation focused on 
section three of the SAQ and included assessment of face 
and content validity, construct validity, internal consistency, 
discriminant validity, concurrent validity and temporal 
stability. 
 Face and content validity were evaluated during cognitive 
debriefing, consisting of face-to-face interviews with breast 
cancer women, where participants were requested for each 
response option, to rate the clarity of terms, their ability to 
discriminate between different aspects of sexual activity 
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(comprehensiveness and redundancy), and the eventual 
intrusive character of questions asked.
 Construct validity was assessed by exploratory factor 
analysis, using PCA with varimax rotation. The Kaiser-
Guttman criterion was used for selecting the number of 
factors to retain.   Internal consistency of each domain was 
assessed by Cronbach’s alpha. 
 The Kruskal-Wallis (two groups) or Mann-Whitney U (> 2 
groups) tests, as appropriate, were used to compare median 
scores in SAQ’s domains to judge discriminant validity. To 
further explore interpretation and analysis of discriminant 
and construct validity, projection of supplementary variables 
on PCA results was used. Projection of hormonal status, 
anxiety and depression scores (HADS), anemia and fatigue 
scores (FACT-An) were analysed on the SAQ domains. 
 Concurrent validity was assessed by forming a priori 
hypothesis on the correlations between the SAQ and 
other covariates. The answers to item seven of the BCPT, 
evaluating pain during intercourse were compared with 
the scores obtained for the discomfort domain of the 
SAQ. Using the same rationale, item G57, of the FACT-An 
evaluating sexual satisfaction (independently of frequency) 
was compared with scores obtained for the pleasure domain 
of the SAQ. 
 Reliability in the form of temporal stability was assessed 
by comparing responses to the SAQ in two different 
time moments through Cohen’s Kappa, and Person’s or 
Spearman’s test, as described.34 In all tests, the significance 
level considered was α = 0.05. 
RESULTS
Face and content validity
 Seven women participated in the cognitive debriefing 
phase, with ages ranging from 28 to 49 years, representing 
a range of educational levels (from ‘no degree’ to ‘university 
degree’) and professional occupations (e.g. administrative 
staff, economist, seamstress, technical analyst, child care, 
housewife).
 All participants considered the questionnaire relevant 
and comprehensive. Most changes suggested consisted 
of adding extra response options in section II, pertaining 
to reasons for sexual inactivity (e.g. not feeling motivated; 
not feeling sexy; my partner rejects my body). One 
participant considered that in the introductory section of the 
questionnaire, assurance of confidentiality was missing. In 
section I, the word “intimate” was considered redundant. 
However, until further validation work is developed, the 
research team decided to maintain the term between 
brackets. In section III, there were two changes proposed 
and adopted (added between brackets for clarification): 
 Question 7: originally worded as ‘This month were you 
satisfied after sexual activity?’ adapted to ‘This month were 
you satisfied after sexual activity (quality)?’ as requested by 
three women (42.9%). 
 Question 10: originally worded as ‘This month were you 
satisfied with the frequency of sexual activity?’ adapted to 
“This month were you satisfied with the frequency of sexual 
activity (quantity)” as requested by four women (57.1%).
Some general comments made are worth mentioning, as 
they may depend on the cultural context:
	  ‘If it were a man asking these questions, I believe I 
wouldn’t feel comfortable… but I would have no problem 
in answering in the paper format (self-administered)’. 
(Participant three, 49 years, primary education, housewife). 
	  ‘It is essential to be briefed on the purpose of such 
questionnaire’. (Participant two, 36 years, university degree, 
economist) 
Table 1 – Demographic, medical and treatment characteristics of 
the sample (n = 134)
Variable
Age at the moment of diagnosis (n = 134) Values
   Mean (standard deviation) 42.8 (5.7)
   Median; mode 44.5; 45
   Minimum; maximum 24; 50
Age at the time of study (n = 134)
   Mean (standard deviation) 47.3 (6.1)
   Median; mode 48.5; 52
   Minimum; maximum 31; 57
Educational level (n = 131) n; %
   First cycle basic education (4 years) 29; 22.1
   Second cycle basic education (6 years) 7; 5.3
   Third cycle basic education (9 years) 27; 20.6
   Secondary education (12 years) 25; 19.1
   University degree 39; 29.8
   Post-graduate studies 4; 3.1
Menopausal status (n = 131) n; %
   Premenopausal 25; 19.1
   Perimenopausal 24; 18.3
   Postmenopausal 82; 62.6
Morphology (n = 134) n; %
  All others 16; 11.9
   Invasive ductal carcinoma 118; 88.1
Treatment (n = 134) n; %
   Chemotherapy (yes) 107; 79.9
   Radiotherapy (yes) 100; 74.6
   Hormonotherapy (yes) 83; 61.9
   Surgery (yes) 134;100.0
Type of Surgery (n = 134) n; %
   Radical mastectomy (yes) 55; 41.0 
   Conservative surgery (yes) 79; 59.0   
Note: Women may have been submitted to more than one surgical procedures
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Other forms of validity and reliability
 A sample of 134 women was constituted, with a mean 
age of 42.8 years, the majority having past menopause 
(n = 82; 62.6%), and having been subject to breast cancer 
surgery (n = 134; 100.0%). Detailed characterization 
of the study recruits is presented in Table 1. Despite the 
menopausal status, no women were taking hormone 
replacement therapy. 
 As various samples have been used, Fig. 1 illustrates 
women comprising each of these samples.
Construct validity 
 PCA indicated the existence of three factors in the 
Portuguese version of the SAQ, as in its original version.34 
These three factor structure explained 75.5% of the 
variance, approximately 10% more than the original. 
Additionally, in the modified version, more than half the 
variance is explained by the pleasure domain (Table 2). The 
distribution of items composing the three domains was quite 
similar to the originally presented in the English version, but 
with differences worth discussing. 
The sexually inactive group
 There were 32 women classifying themselves as 
sexually inactive (23.9%). The main reasons for sexual 
inactivity were lack of interest or motivation (n = 18; 56.3%), 
not having a partner (n = 17; 53.1%), psychological (e.g. 
not feeling well with body image) and physical problems (n 
= 6; 18.8% each), being too tired (n = 4; 12.5%) and partner 
problems (i.e., partner not interested, partner’s rejection or 
partner’s physical problem) (n = 3; 9.4%).
Discriminant validity
 Different subgroups were constituted to test discriminant 
validity.34 Among respondents classifying themselves as 
being sexually active (n = 102), 96 delivered valid, complete 
SAQ-III scores. The pleasure domain mean score was 9.96 
(SD = 4.13; median = 11.0), for the habit domain was 4.55 
(SD = 2.09; median = 4.0) and for the discomfort domain 
was 2.96 (SD = 2.08; median = 3.0).
 Only women having complete information for SAQ-
III (n = 96) and for the co-variable under analysis were 
considered. Therefore, the number included in each sub-
analysis may vary. There were no significant differences 
between age groups for any of the three domains. However, 
women having been through chemotherapy exhibited 
higher levels of habit (p-value = 0.022). Moreover, post-
menopausal women showed significantly higher levels of 
discomfort (p-value = 0.015) and lower levels of habit and 
pleasure, although the latter not significant (p-value > 0.05).
 PCA results were plotted for the three domains retained 
and FACIT-F, FACIT-An, Anxiety and Depression were 
plotted as supplementary variables (variables not included in 
the PCA calculations, but with their coordinates transformed 
accordingly, to illustrate how they fit in PCA results). 
Assuming the first two dimensions, Fig. 2A indicates that 
the scoring for the pleasure dimension (dimension one) 
is positively correlated with quality of life and negatively 
correlated with anxiety and depression, indicating women 
with higher scores of pleasure tend to have higher scores in 
FACIT-F and FACIT-An scales and lower scores in Anxiety 
and Depression scales. Moreover, eight of the items 
composing SAQ are well correlated, suggesting pleasure 
Figure 1 – Flowchart of sample recruits and subsamples analyzed
Respondents
n = 134
Sexually active
n = 102
Excluded
(invalid SAQ responses)
n = 6
Included
n = 96
SAQ-III analysis
n = 96
Temporal stability
n = 73
Sexually inactive
n = 32
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and habit are related and that within the pleasure domain, 
question three is also correlated, although more distant 
(Fig.s 2A and 2B). Dimension two (discomfort) is formed 
by SAQ items five and six, described as components of the 
discomfort domain, and do not show any correlation with 
supplementary variables. In dimension three (habit, Fig.s 
2B or 2C), questions eight, nine and 10 cluster themselves, 
forming a clear construct, where item nine projects itself in 
the opposite direction to item three and fatigue-related QoL 
(Fig. 2C).
Concurrent validity
 The FACT-An includes two questions exploring aspects 
of sexual activity. The item BL4 referring to interest in sex 
was compared to the SAQ’s item ‘Did you desire to have 
sex with your partner(s) this month?’ indicating moderate 
Figure 2 – PCA plots for components 1 - 2 (Pleasure-Discomfort), 2 - 3 (Discomfort-Habit) and 1 - 3 (Pleasure-Habit). Blue variables sign 
supplementary variables projected on PCA results (n = 96)
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Table 2 – Principal Components Analysis (varimax rotation) including Internal Consistency of the SAQ (n = 96) 
Item Weighed factor 
Loadings 
Factor % of 
variance 
explained 
Scale 
if item 
deleted
Inter-item 
correlation
(Standardised 
Chronbach’s alpha)
Was ‘having sex’ an important part of your life this 
month? (q. one)
0.804 
Pleasure 53.1% 
0.564
0.732
Did you enjoy sexual activity this month? (q. two) 0.858 0.526
In general, were you too tired to have sex? 
(q. three)
0.630 0.938
Did you desire to have sex with your partner(s) 
this month? (q. four)
0.789 0.586
In general, did you feel satisfied after sexual 
activity this month? (q. seven)
0.824 0.552
During sexual relations, how frequently did you 
notice dryness of your vagina this month? (q. five)
0.892 
Discomfort 11.6% 
NA
0.839
Did you feel pain or discomfort during penetration 
this month? (q. six)
0.863 NA
How often did you engage in sexual activity this 
month? (q. eight)
0.555 
Habit 10.8% 
0.658
0.739
How did this frequency of sexual activity compare 
with what is usual for you? (q. nine)
0.598 0.729
Were you satisfied with the frequency of sexual 
activity this month? (q. ten)
0.735 0.523
NA: Not applicable
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agreement (and GS7 referring to satisfaction with sex life), 
which were used to judge concurrent validity of the SAQ 
(Pearson’s r = 0.622; Spearman’s rho = 0.645; p-value < 
0.001). The item GS7 referring to satisfaction with sex life 
was compared with SAQ’s item ‘In general, did you feel 
satisfied after sexual activity this month?’ exhibiting even 
better results (Pearson’s r = 0.770; Spearman’s rho = 0.759; 
p-value < 0.001).
 The item in the BCPT judging pain during sexual activity 
was compared with SAQ’s ‘Did you feel pain or discomfort 
during penetration this month?’ resulting in strong 
agreement (Pearson’s r = 0.793; Spearman’s rho = 0.802; 
p-value  < 0.001). The item in the BCPT focusing on vaginal 
dryness was compared with SAQ’s ‘During sexual relations, 
how frequently did you notice dryness of your vagina this 
month?’ showing strong agreement (Pearson’s r = 0.815; 
Spearman’s rho = 0.827; p-value < 0.001).
 Results indicate that concurrent validity of the SAQ is 
high considering the external measures chosen. 
Temporal stability 
 Data from 73 sexually active women responding to SAQ 
in two moments indicates that the temporal stability of all 
items is quite good, where the worse performing item was 
question three (Table 3). 
DISCUSSION
 Breast cancer diagnosis and treatment can be disruptive 
to several aspects of QoL and as the survivor population 
increases, more sensitive tools to evaluate the impact of 
cancer on patients’ lives from their perspective are needed 
to enhance the quality of care provided. This study included 
information from an important patient sample and was the 
first to be developed in the Portuguese population with 
such characteristics. Additionally, the main outcome of the 
study was a patient-reported measure, highlighting the 
current shift in care provision witnessed worldwide. The 
validation results of the SAQ indicate this tool is acceptable 
to participants, despite its intimate nature. The adaptation of 
the SAQ for Portugal resulted in a three factor structure as 
originally described. We tested a one and two factor solution, 
as described by Vistad and colleagues, and concluded the 
three factor solution was better as it described 75% of the 
variance, instead of 53% or 65%, respectively.31 However, 
in our factor solution, all 10 SAQ items loaded into the three 
domains, differently to what was expected. The discomfort 
domain was the same in both versions. There were 
two additional items loading into the habit domain in our 
sample (item eight and 10), transforming this domain into 
a more robust construct including three items and with high 
internal consistency. Consequently, the pleasure domain 
comprised five items, instead of the original six, including 
the fatigue item (question three), which was left out of the 
domain composition in its original. We believe considering 
all items may be a possible strength of our version. The 
option to include question three was confirmed statistically 
and graphically, leading us to think this was the best 
approach in our population. Nonetheless, one must bear in 
mind that the quality of the PCA projection was suboptimal, 
indicating results should be interpreted with caution. 
Regarding the frequency item, this option to include it in the 
habit domain was explained by the fact that Portugal as a 
Latin country may naturally be expected to attribute more 
value to frequency and to consider it an important aspect 
of sexual performance. Moreover, it should be noted that 
the initial version of the SAQ was developed predominantly 
with women without cancer and only validated in women 
having mainly gynaecological cancers. Therefore, it is to 
be expected that it performs differently in breast cancer 
women. Despite these differences, results indicate that 
Table 3 – Temporal stability of the SAQ (n = 73)
Item Pearson’s r Spearman’s rho Cohen’s kappa p-value
Was ‘having sex’ an important part of your life this month? (q. one) 0.875 0.854 0.633 < 0.001
Did you enjoy sexual activity this month? (q. two) 0.828 0.819 0.623 < 0.001
In general, were you too tired to have sex? (q. three) 0.557 0.538 0.444 < 0.001
Did you desire to have sex with your partner(s) this month? (q. four) 0.808 0.777 0.550 < 0.001
During sexual relations, how frequently did you notice dryness of 
your vagina this month? (q. five)
0.799 0.799 0.669 < 0.001
Did you feel pain or discomfort during penetration this month? 
(q. six)
0.899 0.904 0.713 < 0.001
In general, did you feel satisfied after sexual activity this month? 
(q. seven)
0.819 0.825 0.558 < 0.001
How often did you engage in sexual activity this month? (q. eight) 0.775 0.774 0.611 < 0.001
How did this frequency of sexual activity compare with what is usual 
for you? (q. nine)
0.637 0.671 0.592 < 0.001
Were you satisfied with the frequency of sexual activity this month? 
(q. ten)
0.797 0.768 0.590 < 0.001
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the SAQ is valid and reliable for use in Portugal in breast 
cancer survivors, maintaining the original psychometric 
properties.34 Temporal stability results were estimated 
based on a sample larger than originally reported, and 
yielding good estimates in line with published data for 
the original version.34 Nonetheless, additional validation 
in larger samples may help refine the adapted version. 
As mentioned, it is important to note that the validation of 
the adapted version for Portugal was only tested in breast 
cancer survivors. Therefore, results cannot be extrapolated 
to the general population or even to patients diagnosed with 
other cancer types. In the future, it could be interesting to 
additionally test it in gynaecological cancers. One of our 
main findings from using the SAQ was that the prevalence 
of sexual dysfunction among breast cancer survivors was 
24%, in line with the 29% reported in France using the same 
tool in a sample with similar characteristics.38 Considering 
the existing evidence on the benefit of psychosocial 
interventions in improving outcomes of common sequelae 
of breast cancer, including sexual health,39 and as a 
result of the increased awareness of medical doctors 
about sexual dysfunction following this study, a specific 
medical appointment was developed to deal with aspects 
arising from cancer that impact on this important domain 
of a woman’s life. In future research, participants will be 
contacted to evaluate how sexual dysfunction evolved over 
the past five years.
CONCLUSION
 The adapted SAQ is a valid tool for assessing sexual 
activity in Portuguese breast cancer survivors. The results 
of this study were used to modify the structure of care 
previously provided, leading to a more comprehensive 
approach. Additional validation in the overall population and 
in samples with different characteristics is needed.
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